|July 30, 2002
|HEMISPHERX ANNOUNCES DETAILS ON WALL STREET REPORTER ROUNDTABLE SCHEDULED FOR WEDNESDAY JULY 31ST AT 2 PM EST
|Critical Scientific And Investment Related Issues In The Biotech Sector Will Be Discussed By A Panel Of Peers
Philadelphia, PA, Tuesday, July 30, 2002: Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome invites its investors to listen to and participate in a one-hour roundtable conference call discussion, organized by the Wall Street Reporter Magazine.
Three panel speakers, including Dr. William A. Carter, CEO of Hemispherx Biopharma, will focus on different areas in biotechnology, such as the pipeline of products, clinical trials and ongoing research, the platform technology advantages, stock valuation questions, the prospects for investment in biotech stocks this year and for the long term.
The conference call roundtable will be conducted on Wednesday, July 31st at 2:00 pm EST. On the day of the conference call, interested parties may dial into the call at 2:00 pm to listen, and at the end of the conference call there will be a 15 minutes Q&A segment which will allow listeners to ask questions to the panel speakers.
Interested parties in the U.S. and Canada may access the call by dialing (888) 292-5974 or international callers may access the conference by dialing (503) 321-3390, and mentioning the password, which is 1974.
Following the conference there will be published a report including a transcript of the Roundtable, an interview with Dr. Carter, and a full investment profile of the Company.
Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS).
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Robert Giordano, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.